Physician profile
Daniel Ratnarajah
NPI 1023043858
$8,811.95
in general payments reported to CMS, 2019-2025
44 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $705 · 2021: $1,184 · 2022: $1,306 · 2023: $1,499 · 2024: $1,531 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,575.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $808.42 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $735.20 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Pfizer INC. | $705.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $643.71 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $578.77 | 2019-2025 | |
| Novo Nordisk INC | $437.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.16 | 2019-2024 | Synjardy, Spiriva Respimat, Jardiance |
| Lilly USA, LLC | $343.04 | 2020-2025 | Mounjaro, Zepbound, Taltz |
| Astellas Pharma US INC | $332.13 | 2019-2024 | Veozah |
| Janssen Biotech, INC. | $323.06 | 2020-2025 | Tremfya |
| Abbott Laboratories | $207.89 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $198.67 | 2019-2022 | |
| Alk-Abello, INC | $189.91 | 2024-2025 | Odactra, Ragwitek, Grastek |
| Merck Sharp & Dohme LLC | $178.65 | 2019-2023 | Belsomra, Steglatro, Verquvo |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ratnarajah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.